Arkolith/Insider Trading/CRVS/Form 4

Orbimed Advisors LLC

Director, 10% OwnerCorvus Pharmaceuticals, Inc. (CRVS) · full profile →Form 4 · filed Jul 1, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$4.9M
Net Open-Market Flow
-$4.9M
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 27, 2025Sell(S)1.2M$4.16$4.9M7.2M
Jun 27, 2025Option exercise(X)1.4M$3.50$4.9M8.3M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 27, 2025Option exercise(X)1.4M—$00

Transaction Codes

S
Open-market sale
X
Exercise of in-the-money derivative

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000947871-25-000636) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML